Trial Profile
A Study in Healthy Subjects Designed to Evaluate the Pharmacokinetic Profile of Firibastat (QGC001) and Active Metabolites Following Administration of Firibastat (QGC001) Prototype Tablet Formulations
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Firibastat (Primary) ; Firibastat
- Indications Chronic heart failure; Hypertension
- Focus Pharmacokinetics
- Sponsors Quantum Genomics
- 17 Jun 2019 Status changed from active, no longer recruiting to completed.
- 12 Jun 2019 Results presented in a Quantum Genomics media release.
- 25 Feb 2019 Status changed to active, no longer recruiting, according to a Quantum Genomics media release.